Association of laboratory and radiological findings during hospitalization with early post-COVID pulmonary function and exercise capacity: a retrospective study Authors: Sevil Okan, Fatih Okan, Murat Beyhan Published: 2026 ABSTRACT BackgroundThis study aimed to retrospectively evaluate the relationship between demographic characteristics, chest CT findings, and laboratory parameters during hospitalization and post-COVID pulmonary function and exercise capacity.MethodsThe retrospective study included 101 patients who were hospitalized with COVID-19, had CT findings consistent with COVID-19, and completed at least two months after discharge. In the study, Six-Minute Walk Test (6MWT), Pulmonary Function Tests (PFT), thorax CT and laboratory findings were evaluated. Statistical analyses were conducted using SPSS (v25.0); normality and variance homogeneity were assessed by Shapiro–Wilk and Levene tests, respectively, while group comparisons were performed using Student’s t, Mann–Whitney U, Chi-square, and one-way ANOVA with Tukey post-hoc tests, and correlations were evaluated by Spearman analysis.ResultsPatients with severe/critical COVID-19 had significantly higher age, BMI, length of hospital stay, time from diagnosis to admission, ferritin, CRP, D-dimer, neutrophil %, N/L ratio, and Charlson Comorbidity Index, and lower lymphocyte % (p < 0.005). Severe/critical pneumonia was observed in 66.7% of CO-RADS 4 and 67.9% of CO-RADS 5 cases (p = 0.002). Restrictive respiratory patterns were found in 32.7% of the severe/critical group (p = 0.018). ICU patients had significantly shorter 6MWT distances, more frequent restrictive PFT results, and higher inflammatory markers at admission compared to non-ICU patients (p < 0.05). No significant correlation was found between disease severity and 6MWT distance.ConclusionElevated inflammatory markers and ICU admission during hospitalization were associated with impaired pulmonary function and reduced exercise capacity in the early post-COVID period. In contrast, disease severity and CO-RADS classification were not predictive of functional outcomes. These findings highlight the role of inflammatory burden and critical illness as key predictors of post-COVID impairment. Introduction SARS-CoV-2 has caused substantial global morbidity and mortality due to its ability to affect multiple organ systems [1]. As of December 8, 2024, more than 777 million confirmed cases and more than 7 million deaths were reported worldwide [2]. While many individuals survived the acute phase of COVID-19, a significant number experienced lasting effects that negatively impacted their quality of life, including persistent symptoms such as dyspnea, fatigue, cognitive dysfunction, and joint pain [1]. This has given rise to what is now referred to as post-COVID-19 syndrome — a heterogeneous, multisystem condition characterized by a wide array of symptoms that can persist for weeks or months following acute SARS-CoV-2 infection [3]. Although it is difficult to estimate the incidence of post-COVID-19 conditions, data show that about 6% of symptomatic SARS-CoV-2 infections result in post-COVID-19 condition symptoms. The risk of developing these persistent symptoms is significantly higher in those who had severe disease [2]. The length of stay in the intensive care unit (ICU) has also been associated with impaired respiratory function, reduced functional capacity, and decreased quality of life [4]. A meta-analysis showed that 30% of patients report symptoms even two years post-infection [5]. Fatigue, dyspnea, and decreased physical capacity are among the most common long-term effects [6, 7]. Although functional improvements occur within 6 months post-infection, about one-third of patients—especially those with severe disease—still experience symptoms, reduced forced vital capacity (FVC), or low exercise capacity [8]. These functional impairments are often linked to respiratory muscle dysfunction, which can lead to decreased inspiratory strength and increased neural respiratory drive, ultimately impairing performance in functional assessments such as the Six-Minute Walk Test (6MWT) [9]. The 6MWT is widely recognized for its utility in predicting both physical performance and pulmonary function in individuals recovering from COVID-19 [10]. Moreover, elevations in inflammatory biomarkers — indicative of persistent systemic inflammation — have been associated with reduced exercise capacity, possibly due to ongoing impairments in pulmonary and muscle function [11]. SARS-CoV-2 triggers an intense inflammatory response that damages lung tissue and activates coagulation pathways, potentially causing multisystem injury [12, 13]. Early elevated CRP levels predict disease severity, even before radiological changes appear [14]. At three months, patients with residual lung disease after COVID-19 pneumonia showed more critical hospitalizations, longer stays, greater initial CT parenchymal involvement, and more comorbidities. Elevated initial white blood cell counts and leukocytosis were highlighted as potential predictors of chronic pulmonary sequelae [15]. However, existing studies have mostly examined clinical, laboratory, or radiological factors separately, and evidence on their combined role in predicting early post-COVID pulmonary function and exercise capacity remains limited. In addition, data comparing ward and ICU patients are scarce. Therefore, this study aims to evaluate these factors together to identify early predictors of post-COVID impairment and to contribute to appropriate rehabilitation and follow-up strategies. Materials and methods Study design and participant The population of the retrospective study consisted of patients aged 18 years and over, who were admitted to Tokat State Hospital between March 2020 and March 2022, diagnosed with COVID-19, and completed two months after discharge, and whose clinical, radiological and laboratory data could be accessed from the hospital information system. The mean follow-up time after discharge was 104.54 ± 33.88 days for patients with moderate clinical severity and 104.96 ± 31.92 days for patients with severe/critical clinical severity. The study protocols received approval from the Ethical Board of Tokat Gaziosmanpasa University (23-KAEK-216). Based on a study similar to the sample of the present study [16], it was calculated that 101 patients should be taken with a power rate of 80%, error margin of 0.05 and effect size of 0.64 in the t-test using the G*Power 3.1.7 software. In the study, clinical and demographic characteristics, exercise capacities (6MWT), pulmonary function (PFT), radiological findings (Thorax CT) and laboratory data (CRP, D-dimer, ferritin, lymphocyte, neutrophil, neutrophil/lymphocyte) of the patients were evaluated. Criteria for exclusion from the study Presence of malignancy, active infection, moderate or severe heart failure, history of hemorrhagic or ischemic cerebrovascular disease, and disease that restricts mobilization were the reasons for exclusion. Criteria for inclusion in the study Patients who did not have a documented history of chronic lung disease (such as COPD, asthma, or interstitial lung disease) in their medical records prior to the diagnosis of COVID-19, who received inpatient treatment with the diagnosis of COVID-19, who had CT findings compatible with COVID-19 at the time of hospitalization, who were 18 years of age or older who completed at least two months after discharge, and whose research data could be accessed through their medical records were included in the study. As baseline pulmonary function tests were not available, the absence of pre-existing lung disease was determined based on clinical history and medical records. The patients were divided into two groups according to the clinical severity of their disease (based on four severity grades described by the World Health Organization) during hospitalization: 1 = mild or moderate disease with clinical signs of pneumonia and SpO2 ≥ 90% (mild/moderate); 2 = severe disease with pneumonia, SpO2 < 90%, and a respiratory rate > 30 min − 1 or critical disease (i.e., Acute respiratory distress syndrome, sepsis, septic shock, or multi-organ failure) (severe/critical) [17]. Study outcomes Clinical and demographic characteristics data form: Age, gender, body mass index, comorbidity status, the time when the diagnosis of COVID-19 was taken, length of hospital stay and medications used, time of discharge and ICU stay were recorded by the researchers. Six-Minute Walk Test: Physical performance was assessed using 6MWT, which was measured using the standard protocol [18]. Pulmonary function test (PFT): FVC and forced expiratory volume in the first second (FEV1), the FEV1/FVC ratio, forced expiratory flow at 25 and 75% of the pulmonary volume (FEF25–75%), and maximum voluntary ventilation (MVV) measurements were recorded. All PFT measurements were expressed as percentage of predicted normal values (% predicted). The criteria for classifying pulmonary function abnormalities based on ATS guidelines were as follows: normal = both FVC and the FEV1/FVC ratio were in the normal range; obstructive pattern = the FEV1/FVC ratio was < 70% of the normal predicted value, and FEV1 was < 80% of the normal predicted value; restrictive pattern = the FEV1/FVC ratio was ≥ 70% of the normal predicted value. Because the total lung capacity (TLC) was not available, a FVC value of less than 80% was considered a restrictive pattern [19]. Laboratory parameters (CRP, D-dimer, lymphocyte, neutrophil, ferritin): Laboratory data included D-dimer, CRP, ferritin, neutrophil cell count, lymphocyte cell count, neutrophil percentage, lymphocyte percentage and N/L ratio. Blood test measurements were performed within the first 24 h of hospitalization. Thorax computed tomography (CT): Patients who underwent thorax computed tomography at the time of hospital admission and who were PCR (+) due to COVID-19 in the Hospital Image Archiving and Communication System (PACS) between 2020 and 2022 were retrospectively screened. All CT images were evaluated by a 12-year specialist radiologist. The examination was performed in the supine position with non-contrast CT using a 128-slice CT (General Electric Healthcare) device with 100 kV, 75 mAs and 5 mm slice thickness. The COVID-19 Reporting and Data System (CO-RADS), a procedure based on recommendations from the Radiological Society of North America, was published by the Radiological Society of the Netherlands (NVvR) in 2020. From the lowest level of suspicion (CO-RADS 1) to the highest level of suspicion (CO-RADS 5), a scoring system from 0 to 5 was used with this method to classify COVID-19 lung involvement on CT [20] (Fig. 1). CO-RADS 0 is used to indicate technical insufficiency when the CT scan cannot be reliably interpreted. Regarding CO-RADS, although primarily designed as a diagnostic classification system, previous studies have demonstrated its prognostic value. For instance, a prospective, multicenter study reported that CO-RADS and CT Severity Score (CTSS) were significantly associated with ICU admission and 30-day mortality [21]. Moreover, CO-RADS grades have been shown to differ significantly between survivors and non-survivors, supporting its use as a marker of disease severity [22]. Fig. 1Non-contrast chest computed tomography examination shows ground-glass opacities (white arrows) and consolidation (black arrows) compatible with A) CO-RADS 3, B) CO-RADS 4, C) CO-RADS 5 Non-contrast chest computed tomography examination shows ground-glass opacities (white arrows) and consolidation (black arrows) compatible with A) CO-RADS 3, B) CO-RADS 4, C) CO-RADS 5 Statistical analyses Statistical analyses of the data obtained in the study were carried out using SPSS software (Version 25.0, SPSS Inc., Chicago, IL, USA). The normality distribution was examined by the Shapiro-Wilk test and the homogeneity of the variances was examined by the Levene test. Descriptive statistics were presented as the mean ± standard deviation for normally distributed continuous data and as median (Q1-Q3) for normally distributed continuous data. Chi-square test and Chi-square test with Yates correction were used to compare the proportions of categorical variables between the study groups. Spearman correlation analysis was used to determine the relationship between variables. Student’s t test was used to compare normally distributed quantitative data, and Mann Whitney U test was used to compare non-normally distributed parameters of the groups. One-way analysis of variance was used to compare groups for continuous data. Tukey’s Honest Significant Difference test was used for multiple comparisons. p < 0.05 was considered statistically significant. Results The mean age of the participants was 51.65 ± 12.35 years (range: 22–77), with 50.5% (n: 51) being female. The proportion of males classified as having severe/critical clinical severity (60.0%) was significantly higher than that of females (40.0%) (p: 0.035). Additionally, patients with severe/critical clinical severity had significantly higher mean age, body mass index (BMI), and length of hospital stay compared to those with moderate clinical severity (p: 0.001).The median time of hospital admission after diagnosis was 2.00 days (Q1–Q3: 1–10) in the moderate clinical severity group and 5.00 days (Q1–Q3: 1–11) in the severe/critical clinical severity group, with a statistically significant difference between the groups (U:980.000, p:0.049). The Charlson Comorbidity Index was found to be significantly higher in patients with severe/critical clinical severity compared to those with moderate clinical severity (p:0.001) (Table 1). Table 1Distribution of descriptive characteristics and clinical features of patients based on clinical severityClinical severityTestModerateSevere/critical% (n)%(n)GenderFemale63.0 (29)40.0 (22)x2: 4.439p: 0.035†Male27.0 (17)60.0 (33)Smoking statusNo87.0 (40)89.1 (49)x2: 0.109p: 0.983Yes13.0 (6)10.9 (6)Presence of chronic diseaseNo54.3 (25)41.8 (23)x2: 1.114p: 0.291†Yes45.7 (21)58.2 (32)Steroid useNo80.4 (37)34.5 (19)x2: 19.536p: 0.001†Yes19.6(9)65.5 (36)Immune plasma useNo97.8 (45)74.5 (41)x2: 8.974p: 0.003*Yes2.2 (1)25.5 (14)Age (years) (Mean ± SD)46.50 ± 13.0755.96 ± 9.92t: -4.132p: 0.001‡BMI (Mean ± SD)29.55 ± 5.2032.65 ± 4.09t: -3.354p: 0.001‡Length of hospital stay (days) (Mean ± SD)7.43 ± 3.7913.36 ± 5.48t: -6.189p: 0.001‡Days since COVID-19 diagnosis (Mean ± SD)104.54 ± 33.88104.96 ± 31.92t: -0.064p: 0.949‡Charlson Comorbidity Index Median (Q1-Q3)1.00(0–4)2.00(0–4)U:814.500 p:0.001§Time of hospital admission after diagnosis Median (Q1-Q3)2.00(1–10)5.00(1–11)U:980.000P:0.049§IQR Interquartile IQR. Q1-Q3)*Yates corrected chi-square test†Pearson Chi-Square test‡Student t test was used§Mann-Whitney U test was used Table 1Distribution of descriptive characteristics and clinical features of patients based on clinical severityClinical severityTestModerateSevere/critical% (n)%(n)GenderFemale63.0 (29)40.0 (22)x2: 4.439p: 0.035†Male27.0 (17)60.0 (33)Smoking statusNo87.0 (40)89.1 (49)x2: 0.109p: 0.983Yes13.0 (6)10.9 (6)Presence of chronic diseaseNo54.3 (25)41.8 (23)x2: 1.114p: 0.291†Yes45.7 (21)58.2 (32)Steroid useNo80.4 (37)34.5 (19)x2: 19.536p: 0.001†Yes19.6(9)65.5 (36)Immune plasma useNo97.8 (45)74.5 (41)x2: 8.974p: 0.003*Yes2.2 (1)25.5 (14)Age (years) (Mean ± SD)46.50 ± 13.0755.96 ± 9.92t: -4.132p: 0.001‡BMI (Mean ± SD)29.55 ± 5.2032.65 ± 4.09t: -3.354p: 0.001‡Length of hospital stay (days) (Mean ± SD)7.43 ± 3.7913.36 ± 5.48t: -6.189p: 0.001‡Days since COVID-19 diagnosis (Mean ± SD)104.54 ± 33.88104.96 ± 31.92t: -0.064p: 0.949‡Charlson Comorbidity Index Median (Q1-Q3)1.00(0–4)2.00(0–4)U:814.500 p:0.001§Time of hospital admission after diagnosis Median (Q1-Q3)2.00(1–10)5.00(1–11)U:980.000P:0.049§IQR Interquartile IQR. Q1-Q3)*Yates corrected chi-square test†Pearson Chi-Square test‡Student t test was used§Mann-Whitney U test was used Distribution of descriptive characteristics and clinical features of patients based on clinical severity x2: 4.439 p: 0.035† x2: 0.109 p: 0.983 x2: 1.114 p: 0.291† x2: 19.536 p: 0.001† x2: 8.974 p: 0.003* t: -4.132 p: 0.001‡ t: -3.354 p: 0.001‡ t: -6.189 p: 0.001‡ t: -0.064 p: 0.949‡ 1.00 (0–4) 2.00 (0–4) 2.00 (1–10) 5.00 (1–11) U:980.000 P:0.049§ IQR Interquartile IQR. Q1-Q3) *Yates corrected chi-square test †Pearson Chi-Square test ‡Student t test was used §Mann-Whitney U test was used According to PFT data, a restrictive pulmonary pattern was observed in 10.9% of patients with moderate clinical severity and in 32.7% of those with severe/critical severity (p: 0.018). Mean FEV1 and FVC values were significantly lower in patients with severe/critical clinical severity compared to those with moderate severity (p: 0.002 and p: 0.001, respectively). Additionally, median levels of ferritin, CRP, D-dimer, neutrophil %, neutrophil count, and N/L ratio were significantly higher, while median lymphocyte % was significantly lower (p: 0.001) in the severe/critical group compared to the moderate group (Table 2). Diabetes was present in 8 (30.8%) moderate and 18 (69.2%) severe/critical patients. Hypertension was observed in 11 (33.3%) moderate and 22 (66.7%) severe/critical patients. Coronary artery disease was seen in 3 (33.3%) moderate and 6 (66.7%) severe/critical patients. Hypothyroidism was detected in 4 (80.0%) moderate and 1 (20.0%) severe/critical patient. Table 2Pulmonary function test and laboratory parameter findings of the patients in different clinical severitiesClinical severityTestModerateSevere/critical%(n)%(n)PFT stageNormal89.1 (41)67.3 (37)x2:5.619p:0.018†Restrictive10.9 (5)32.7 (18)FEV1 (Mean ± SD)94.39 ± 12.3585.85 ± 14.30t:3.176p:0.002‡FVC (Mean ± SD)91.52 ± 11.0781.56 ± 13.90t:3.926p0.001‡FEV1/FVC (Mean ± SD)103.65 ± 6.68105.35 ± 6.90t-1.246p:0.216‡FEF%25–75 (Mean ± SD)106.39 ± 26.34108.33 ± 32.33t:-0.326p:0.745‡MVV (Mean ± SD)84.23 ± 17.1385.27 ± 20.60t:-0.274p:0.785‡6MWT (m) (Mean ± SD)424.20 ± 73.94415.78 ± 80.05t:0.545p:0.587‡Ferritin ml/ngMedian (Q1-Q3)90.11(47.33-220.49)385.00(224.18-1024.50)U:600.000p:0.001§CRP mg/LMedian (Q1-Q3)18.77(7.97–48.42)98.00(58.00-128.42)U:468.500p:0.001§D-Dimer (mg/L)Median (Q1-Q3)0.22(0.09–0.55)0.43(0.26–1.51)U:713.500 p:0.001§Neutrophil %Median (Q1-Q3)64.35(57.16–71.80)78.30(69.60–86.90)U:563.000 p:0.001§Lymphocyte %Median (Q1-Q3)26.50(18.60-33.95)16.80(9.30–22.30)U:621.500 p:0.001§Neutrophil CountMedian (Q1-Q3)3.95(3.22–4.77)5.37(3.88–8.85)U:671.000 p:0.001§Lymphocyte CountMedian (Q1-Q3)1.39(0.96–2.10)1.14(0.80–1.50)U:981.000 p:0.053§Neutrophil/LymphocyteMedian (Q1-Q3)2.52(1.74–4.76)4.68(3.13–9.33)U:702.500p:0.001§IQR Interquartile range. (Q1-Q3)†Pearson Chi-Square test was used‡Student t test was used§Mann-Whitney U test was used Table 2Pulmonary function test and laboratory parameter findings of the patients in different clinical severitiesClinical severityTestModerateSevere/critical%(n)%(n)PFT stageNormal89.1 (41)67.3 (37)x2:5.619p:0.018†Restrictive10.9 (5)32.7 (18)FEV1 (Mean ± SD)94.39 ± 12.3585.85 ± 14.30t:3.176p:0.002‡FVC (Mean ± SD)91.52 ± 11.0781.56 ± 13.90t:3.926p0.001‡FEV1/FVC (Mean ± SD)103.65 ± 6.68105.35 ± 6.90t-1.246p:0.216‡FEF%25–75 (Mean ± SD)106.39 ± 26.34108.33 ± 32.33t:-0.326p:0.745‡MVV (Mean ± SD)84.23 ± 17.1385.27 ± 20.60t:-0.274p:0.785‡6MWT (m) (Mean ± SD)424.20 ± 73.94415.78 ± 80.05t:0.545p:0.587‡Ferritin ml/ngMedian (Q1-Q3)90.11(47.33-220.49)385.00(224.18-1024.50)U:600.000p:0.001§CRP mg/LMedian (Q1-Q3)18.77(7.97–48.42)98.00(58.00-128.42)U:468.500p:0.001§D-Dimer (mg/L)Median (Q1-Q3)0.22(0.09–0.55)0.43(0.26–1.51)U:713.500 p:0.001§Neutrophil %Median (Q1-Q3)64.35(57.16–71.80)78.30(69.60–86.90)U:563.000 p:0.001§Lymphocyte %Median (Q1-Q3)26.50(18.60-33.95)16.80(9.30–22.30)U:621.500 p:0.001§Neutrophil CountMedian (Q1-Q3)3.95(3.22–4.77)5.37(3.88–8.85)U:671.000 p:0.001§Lymphocyte CountMedian (Q1-Q3)1.39(0.96–2.10)1.14(0.80–1.50)U:981.000 p:0.053§Neutrophil/LymphocyteMedian (Q1-Q3)2.52(1.74–4.76)4.68(3.13–9.33)U:702.500p:0.001§IQR Interquartile range. (Q1-Q3)†Pearson Chi-Square test was used‡Student t test was used§Mann-Whitney U test was used Pulmonary function test and laboratory parameter findings of the patients in different clinical severities x2:5.619 p:0.018† t:3.176 p:0.002‡ t:3.926 p0.001‡ t-1.246 p:0.216‡ t:-0.326 p:0.745‡ t:-0.274 p:0.785‡ t:0.545 p:0.587‡ Ferritin ml/ng Median (Q1-Q3) 90.11 (47.33-220.49) 385.00 (224.18-1024.50) U:600.000 p:0.001§ CRP mg/L Median (Q1-Q3) 18.77 (7.97–48.42) 98.00 (58.00-128.42) U:468.500 p:0.001§ D-Dimer (mg/L) Median (Q1-Q3) 0.22 (0.09–0.55) 0.43 (0.26–1.51) Neutrophil % Median (Q1-Q3) 64.35 (57.16–71.80) 78.30 (69.60–86.90) Lymphocyte % Median (Q1-Q3) 26.50 (18.60-33.95) 16.80 (9.30–22.30) Neutrophil Count Median (Q1-Q3) 3.95 (3.22–4.77) 5.37 (3.88–8.85) Lymphocyte Count Median (Q1-Q3) 1.39 (0.96–2.10) 1.14 (0.80–1.50) Neutrophil/Lymphocyte Median (Q1-Q3) 2.52 (1.74–4.76) 4.68 (3.13–9.33) U:702.500 p:0.001§ IQR Interquartile range. (Q1-Q3) †Pearson Chi-Square test was used ‡Student t test was used §Mann-Whitney U test was used The mean age and length of hospital stay were significantly lower in patients with CO-RADS 2 compared to those in other CO-RADS categories (p:0.002 and p:0.014, respectively). In the CO-RADS 2 category, 78.9% of patients had moderate clinical severity, whereas in the CO-RADS 4 and CO-RADS 5 categories, 66.7% and 67.9% of patients, respectively, experienced severe/critical clinical stages of the disease (p:0.002) (Table 3). Table 3Clinical findings of the patients in different CO-RADS CategoryCO-RADS categoryCO-RADS 2CO-RADS 3CO-RADS 4CO-RADS 5n:19n:17n:9n:56(Mean ± SD)(Mean ± SD)(Mean ± SD)(Mean ± SD)Age42.16 ± 16.86a54.76 ± 12.39b55.33 ± 7.77b53.34 ± 9.56bF:5.331; p:0.0026MWT (m)423.89 ± 75.27419.59 ± 65.40423.78 ± 101.97417.50 ± 78.56F:0.041; p:0.989 #Length of hospital stay (days)7.53 ± 4.10a9.53 ± 5.00b13.22 ± 3.93b11.66 ± 6.04bF:3.692; p:0.014 #BMI30.05 ± 6.1931.94 ± 5.0531.46 ± 4.0031.40 ± 4.47F:0.517; p:0.672 #Days since COVID-19 diagnosis110.32 ± 4.68101.06 ± 25.68101.78 ± 30.51104.50 ± 34.67 F:0.276; p:0.843 #FEV193.74 ± 11.5488.53 ± 16.8799.22 ± 13.6988.36 ± 14.01 F:0.821; p:0.483 #FVC90.16 ± 8.4885.29 ± 17.1787.11 ± 14.4384.80 ± 13.70 F:0.767; p:0.515 #FEV1/FVC103.74 ± 6.58104.53 ± 8.34106.11 ± 4.25104.63 ± 6.84 F:0.243; p:0.866 #FEF25-FEF75102.37 ± 18.59100.06 ± 24.71120.56 ± 23.73109.30 ± 34.15 F:1.206; p:0.312 #MVV86.18 ± 19.7173.47 ± 17.3088.33 ± 15.5087.20 ± 18.97 F:2.559; p:0.059 #Clinical severity Moderate %(n)78.9 (15)58.8(10)33.3 (3)32.1(18) Severe/critical %(n)21.1(4)41.2(7)66.7(6)67.9(38) x2:14.368; p:0.002†PFT stage Normal89.5(17)76.5(13)88.9(8)71.4(40) Restrictive10.5(2)23.5(4)11.1 (1)28.6(16)x2:3.392; p:0.335†a, b, c: Means with the same letter are not statistically different#One-way analysis of variance was used, †Pearson Chi-Square test was used Table 3Clinical findings of the patients in different CO-RADS CategoryCO-RADS categoryCO-RADS 2CO-RADS 3CO-RADS 4CO-RADS 5n:19n:17n:9n:56(Mean ± SD)(Mean ± SD)(Mean ± SD)(Mean ± SD)Age42.16 ± 16.86a54.76 ± 12.39b55.33 ± 7.77b53.34 ± 9.56bF:5.331; p:0.0026MWT (m)423.89 ± 75.27419.59 ± 65.40423.78 ± 101.97417.50 ± 78.56F:0.041; p:0.989 #Length of hospital stay (days)7.53 ± 4.10a9.53 ± 5.00b13.22 ± 3.93b11.66 ± 6.04bF:3.692; p:0.014 #BMI30.05 ± 6.1931.94 ± 5.0531.46 ± 4.0031.40 ± 4.47F:0.517; p:0.672 #Days since COVID-19 diagnosis110.32 ± 4.68101.06 ± 25.68101.78 ± 30.51104.50 ± 34.67 F:0.276; p:0.843 #FEV193.74 ± 11.5488.53 ± 16.8799.22 ± 13.6988.36 ± 14.01 F:0.821; p:0.483 #FVC90.16 ± 8.4885.29 ± 17.1787.11 ± 14.4384.80 ± 13.70 F:0.767; p:0.515 #FEV1/FVC103.74 ± 6.58104.53 ± 8.34106.11 ± 4.25104.63 ± 6.84 F:0.243; p:0.866 #FEF25-FEF75102.37 ± 18.59100.06 ± 24.71120.56 ± 23.73109.30 ± 34.15 F:1.206; p:0.312 #MVV86.18 ± 19.7173.47 ± 17.3088.33 ± 15.5087.20 ± 18.97 F:2.559; p:0.059 #Clinical severity Moderate %(n)78.9 (15)58.8(10)33.3 (3)32.1(18) Severe/critical %(n)21.1(4)41.2(7)66.7(6)67.9(38) x2:14.368; p:0.002†PFT stage Normal89.5(17)76.5(13)88.9(8)71.4(40) Restrictive10.5(2)23.5(4)11.1 (1)28.6(16)x2:3.392; p:0.335†a, b, c: Means with the same letter are not statistically different#One-way analysis of variance was used, †Pearson Chi-Square test was used Clinical findings of the patients in different CO-RADS Category a, b, c: Means with the same letter are not statistically different #One-way analysis of variance was used, †Pearson Chi-Square test was used Significant strong positive correlations were observed between CRP and ferritin levels, as well as between FEV1 and FVC values. Additionally, significant correlations were found between the N/L ratio and FVC, and FEV1/FVC values. A significant positive correlation was also identified between FEV1, FVC, and 6MWT distance (Table 4). Table 4The relationship between laboratory parameters and PFT, 6MWTCRPD-DimerN/LFVCFEV1FEV1/FVC6 MWTFerritinr:0.614**p:0.000r:0.575**p:0.000r:0.359**p:0.000r:-0.268**p:0.007r:-0.211*p:0.035r:0.067p:0.507r:-0.131p:0.193CRPr:0.524**p:0.000r:0.519**p:0.000r:-0.260**p:0.009r:-0.207*p:0.038r:0.092p:0.358r:-0.099p:0.323D-Dimerr:0.240*p:0.016r:-0.035 p:0.725r:0.035p:0.726r:0.051p:0.613r:0.043p:0.666N/Lr:-0.251*p:0.011r:-0.141p:0.159r:0.314**p:0.001r:0.048p:0.630FVCr:0.920**p:0.000r:-0.166 p:0.097r:0.359**p:0.000FEV1r:0.150p:0.134r:0.410**p:0.000FEV1/FVCr:0.083p:0.410*Correlation is significant at 0.05 level (2-tailed)**Correlation is significant at 0.01 level (2-tailed) Table 4The relationship between laboratory parameters and PFT, 6MWTCRPD-DimerN/LFVCFEV1FEV1/FVC6 MWTFerritinr:0.614**p:0.000r:0.575**p:0.000r:0.359**p:0.000r:-0.268**p:0.007r:-0.211*p:0.035r:0.067p:0.507r:-0.131p:0.193CRPr:0.524**p:0.000r:0.519**p:0.000r:-0.260**p:0.009r:-0.207*p:0.038r:0.092p:0.358r:-0.099p:0.323D-Dimerr:0.240*p:0.016r:-0.035 p:0.725r:0.035p:0.726r:0.051p:0.613r:0.043p:0.666N/Lr:-0.251*p:0.011r:-0.141p:0.159r:0.314**p:0.001r:0.048p:0.630FVCr:0.920**p:0.000r:-0.166 p:0.097r:0.359**p:0.000FEV1r:0.150p:0.134r:0.410**p:0.000FEV1/FVCr:0.083p:0.410*Correlation is significant at 0.05 level (2-tailed)**Correlation is significant at 0.01 level (2-tailed) The relationship between laboratory parameters and PFT, 6MWT r:0.614** p:0.000 r:0.575** p:0.000 r:0.359** p:0.000 r:-0.268** p:0.007 r:-0.211* p:0.035 r:0.067 p:0.507 r:-0.131 p:0.193 r:0.524** p:0.000 r:0.519** p:0.000 r:-0.260** p:0.009 r:-0.207* p:0.038 r:0.092 p:0.358 r:-0.099 p:0.323 r:0.240* p:0.016 r:0.035 p:0.726 r:0.051 p:0.613 r:0.043 p:0.666 r:-0.251* p:0.011 r:-0.141 p:0.159 r:0.314** p:0.001 r:0.048 p:0.630 r:0.920** p:0.000 r:0.359** p:0.000 r:0.150 p:0.134 r:0.410** p:0.000 FEV1/ FVC r:0.083 p:0.410 *Correlation is significant at 0.05 level (2-tailed) **Correlation is significant at 0.01 level (2-tailed) Significant differences were observed in PFT, exercise capacity, and laboratory parameters between individuals who required ICU and those who did not. According to PFT results, a restrictive pattern was significantly more prevalent in the ICU group (p : 0.026). Additionally, FEV₁ and FVC values were significantly reduced in this group, with both showing p : 0.001. A slight but statistically significant increase was noted in the FEV₁/FVC ratio (p : 0.047). No significant differences were found between the groups in other respiratory parameters, such as FEF25-75% and MVV (p : 0.363 and p : 0.761, respectively). Exercise capacity, assessed by the 6MWT, was significantly lower in patients who required ICU (p : 0.003), indicating decreased physical endurance. Regarding laboratory findings, patients in the ICU group exhibited significantly higher levels of ferritin (p = 0.001), CRP (p = 0.015), D-dimer (p = 0.001), neutrophil % (p = 0.009), and N/L ratio (p = 0.046), while lymphocyte % (p = 0.034) and lymphocyte count (p = 0.014) were significantly lower compared to non-ICU patients. These results suggest a more pronounced systemic inflammatory and immune response in patients requiring ICU. Other laboratory parameters did not show statistically significant differences (Table 5). All ICU patients were in the severe/critical disease category; however, not all patients classified as severe/critical required ICU admission, indicating that ICU analyses partially overlap with but are not identical to disease severity analyses. Table 5Comparison of PFT, exercise capacity, and laboratory parameters according to ICU admission statusICUTestNoYes%(n)%(n)PFT stageNormal81.7(67)57.9(11)x2: 4.974p: 0.026†Restrictive18.3 (15)42.1 (8)FEV1 (Mean ± SD)91.87 ± 12.6080.58 ± 16.52t: 3.358p: 0.001‡FVC (Mean ± SD)88.63 ± 11.5675.16 ± 16.34t: 4.211p: 0.001‡FEV1/FVC (Mean ± SD)103.93 ± 6.63107.37 ± 7.10t: -2.012p: 0.047‡FEF%25–75 (Mean ± SD)106.15 ± 26.73113.05 ± 40.24t: -0.915p: 0.363‡MVV (Mean ± SD)85.19 ± 16.3283.11 ± 28.40t: 0.308p: 0.761‡6MWT (m) (Mean ± SD)439.10 ± 51.30361.84 ± 95.58t: 3.411p: 0.003‡Ferritin ml/ngMedian (Q1-Q3)187.45(14.60–2000.00)913.51(40.49–2000.00)U:345.000p:0.001§CRP mg/LMedian (Q1-Q3)44.50(2.00-191.00)88.78(18.00-147.00)U:499.500p:0.015§D-Dimer (mg/L)Median (Q1-Q3)0.29(0.01–3.90)0.92(0.14–3.90)U:372.000 p:0.001§Neutrophil %Median (Q1-Q3)69.95(42.40–92.70)80.10(59.40–94.10)U:479.500 p:0.009§Lymphocyte%Median (Q1-Q3)21.40(5.90–46.60)15.30(3.30–34.00)U:535.000 p:0.034§Neutrophil Count Median (Q1-Q3)4.38(0.60-12.65)4.69(1.36–12.35)U:721.500 p:0.617§Lymphocyte CountMedian (Q1-Q3)1.32(0.14–2.89)0.84(0.31–2.04)U:497.500 p:0.014§Neutrophil / LymphocyteMedian (Q1-Q3)3.43(0.91–21.07)5.23(1.76–28.72)U:549.500p:0.046§IQR Interquartile range. (Q1-Q3)†Pearson Chi-Square test was used‡Student t test was used§ Mann-Whitney U test was used Table 5Comparison of PFT, exercise capacity, and laboratory parameters according to ICU admission statusICUTestNoYes%(n)%(n)PFT stageNormal81.7(67)57.9(11)x2: 4.974p: 0.026†Restrictive18.3 (15)42.1 (8)FEV1 (Mean ± SD)91.87 ± 12.6080.58 ± 16.52t: 3.358p: 0.001‡FVC (Mean ± SD)88.63 ± 11.5675.16 ± 16.34t: 4.211p: 0.001‡FEV1/FVC (Mean ± SD)103.93 ± 6.63107.37 ± 7.10t: -2.012p: 0.047‡FEF%25–75 (Mean ± SD)106.15 ± 26.73113.05 ± 40.24t: -0.915p: 0.363‡MVV (Mean ± SD)85.19 ± 16.3283.11 ± 28.40t: 0.308p: 0.761‡6MWT (m) (Mean ± SD)439.10 ± 51.30361.84 ± 95.58t: 3.411p: 0.003‡Ferritin ml/ngMedian (Q1-Q3)187.45(14.60–2000.00)913.51(40.49–2000.00)U:345.000p:0.001§CRP mg/LMedian (Q1-Q3)44.50(2.00-191.00)88.78(18.00-147.00)U:499.500p:0.015§D-Dimer (mg/L)Median (Q1-Q3)0.29(0.01–3.90)0.92(0.14–3.90)U:372.000 p:0.001§Neutrophil %Median (Q1-Q3)69.95(42.40–92.70)80.10(59.40–94.10)U:479.500 p:0.009§Lymphocyte%Median (Q1-Q3)21.40(5.90–46.60)15.30(3.30–34.00)U:535.000 p:0.034§Neutrophil Count Median (Q1-Q3)4.38(0.60-12.65)4.69(1.36–12.35)U:721.500 p:0.617§Lymphocyte CountMedian (Q1-Q3)1.32(0.14–2.89)0.84(0.31–2.04)U:497.500 p:0.014§Neutrophil / LymphocyteMedian (Q1-Q3)3.43(0.91–21.07)5.23(1.76–28.72)U:549.500p:0.046§IQR Interquartile range. (Q1-Q3)†Pearson Chi-Square test was used‡Student t test was used§ Mann-Whitney U test was used Comparison of PFT, exercise capacity, and laboratory parameters according to ICU admission status x2: 4.974 p: 0.026† t: 3.358 p: 0.001‡ t: 4.211 p: 0.001‡ t: -2.012 p: 0.047‡ t: -0.915 p: 0.363‡ t: 0.308 p: 0.761‡ t: 3.411 p: 0.003‡ Ferritin ml/ng Median (Q1-Q3) 187.45 (14.60–2000.00) 913.51 (40.49–2000.00) U:345.000 p:0.001§ CRP mg/L Median (Q1-Q3) 44.50 (2.00-191.00) 88.78 (18.00-147.00) U:499.500 p:0.015§ D-Dimer (mg/L) Median (Q1-Q3) 0.29 (0.01–3.90) 0.92 (0.14–3.90) Neutrophil % Median (Q1-Q3) 69.95 (42.40–92.70) 80.10 (59.40–94.10) Lymphocyte % Median (Q1-Q3) 21.40 (5.90–46.60) 15.30 (3.30–34.00) 4.38 (0.60-12.65) 4.69 (1.36–12.35) Lymphocyte Count Median (Q1-Q3) 1.32 (0.14–2.89) 0.84 (0.31–2.04) Neutrophil / Lymphocyte Median (Q1-Q3) 3.43 (0.91–21.07) 5.23 (1.76–28.72) U:549.500 p:0.046§ IQR Interquartile range. (Q1-Q3) †Pearson Chi-Square test was used ‡Student t test was used § Mann-Whitney U test was used The median ferritin level of patients in the CO-RADS 2 category was significantly lower compared to those in other CO-RADS categories (KW: 15.980; p:0.001). Similarly, the median CRP level in the CO-RADS 2 group was significantly lower than in other categories (KW :19.428; p:0.001). Additionally, the median D-dimer level in CO-RADS 2 patients was significantly lower than that of patients in other CO-RADS categories (KW :13.841; p:0.003) (Fig. 2). Fig. 2Relationship between CO-RADS category and CRP, Ferritin, D-Dimer levels Relationship between CO-RADS category and CRP, Ferritin, D-Dimer levels Discussion Clinical severity of COVID-19 varies according to gender, age, and BMI. In the present study, male patients were more likely to exhibit severe or critical forms of COVID-19. Similarly, a study conducted in Wuhan reported that older men were at higher risk of severe and potentially fatal respiratory complications, including acute respiratory distress syndrome [23]. Another investigation assessing gender-related differences found that although the incidence of COVID-19 was comparable between men and women, men tended to develop more severe disease and faced a greater risk of adverse outcomes and mortality regardless of age [24]. Consistent with these findings, our study showed that patients with severe/critical COVID-19 were older and had higher BMI values, supporting age and obesity as significant risk factors for poor prognosis. Supporting this, research from Wuhan indicated that ICU-admitted patients were generally older [25], and a large prospective cohort study from England demonstrated a significant positive association between increased BMI and ICU admission [26]. Collectively, these findings indicate that male sex, advanced age, and elevated BMI are important risk factors for progression to severe/critical COVID-19. In our study, the Charlson Comorbidity Index was significantly higher in patients with severe/critical clinical severity compared to those with moderate severity, highlighting the impact of comorbidities on disease progression. A systematic review and meta-analysis reported similar findings, with higher Charlson Comorbidity Index scores associated with increased clinical severity and mortality [27]. These results underscore the importance of assessing comorbidities upon hospital admission to better predict outcomes. Patients with ICU admission demonstrated shorter 6MWT distances, more pronounced restrictive patterns on PFT post-discharge, and higher inflammatory laboratory parameters at admission (CRP, D-dimer, ferritin, neutrophil %, and N/L ratio) compared to non-ICU patients. Previous studies reported that elevated inflammatory markers at admission correlate with increased clinical severity and mortality, and that patients with severe COVID-19 may continue to experience impaired pulmonary function, reduced physical capacity, and fatigue months after ICU discharge [4, 28]. These findings suggest that severe acute illness requiring intensive care is linked to sustained functional impairment, while heightened inflammatory responses are mainly observed during the acute phase. Although no significant association was found between overall disease severity and 6MWT distance in our cohort, patients requiring ICU admission demonstrated notably reduced exercise capacity. This distinction indicates that while general clinical severity may not fully predict early post-COVID functional performance, the need for intensive care—reflecting more severe acute illness—serves as a more sensitive indicator of early post-discharge physical impairment. Therefore, ICU admission appears to be a critical factor in identifying patients at risk for reduced exercise capacity, independent of the broader clinical severity classification. These findings underscore the importance of closely monitoring ICU survivors and implementing early post-COVID rehabilitation strategies to improve functional recovery. SARS-CoV-2 primarily affects lymphocytes, particularly T lymphocytes, triggering cytokine storms that alter peripheral white blood cells [23]. In our study, patients with severe/critical COVID-19 exhibited elevated CRP, ferritin, D-dimer, neutrophil %, and N/L ratio, alongside reduced lymphocyte %. Previous research reported lymphopenia in 75.4% of COVID-19 patients, elevated CRP in 91.9%, and increased D-dimer in 43.2% during the acute phase [29] and lymphopenia has been associated with ICU admission [30]. Additionally, neutrophil count and N/L ratio have been correlated with disease severity [30, 31]. The neutrophilia may reflect the cytokine storm induced by viral invasion, while coagulation activation may result from the persistent inflammatory response [25]. Elevated D-dimer levels have also been linked to adverse outcomes in COVID-19 [32]. These mechanisms may explain the higher inflammatory markers in patients with greater clinical severity. CRP, a robust inflammatory marker, correlates with FVC, 6MWT distance, and dyspnea scores in severe COVID-19 [4]. Consistent with this, our study found significant correlations between CRP and ferritin levels and FEV1 and FVC values, and between N/L ratio and FVC and FEV1/FVC values. Persistent inflammation and fibrotic changes may underlie long-term pulmonary dysfunction in severe cases [33]. These findings highlight the prognostic significance of inflammatory markers at hospital admission in predicting clinical severity, ICU requirement, and early post-COVID period pulmonary outcomes in patients with COVID-19. CO-RADS classification was used to standardize assessment of pulmonary involvement on non-enhanced chest CT [34]. Patients with severe/critical disease were predominantly in CO-RADS categories 4 or 5. Higher CO-RADS categories may reflect greater pulmonary involvement and disease severity, aligning with previous studies comparing radiological scores across disease severities [35–38]. Overall, CO-RADS classification in the acute phase of COVID-19 may provide prognostic insight into early clinical status, inflammatory burden, and the likelihood of ICU admission. In terms of PFT abnormalities, the present study demonstrated that FEV1 and FVC values were significantly lower in the severe/critical group compared to the moderate group, with significantly a higher prevalence of restrictive ventilatory patterns. These findings are consistent with a systematic review and meta-analysis by Long et al., which reported reduced FEV1 and FVC values among patients with severe disease in studies with follow-up durations exceeding one month post-discharge or two months post-hospitalization [39]. Similarly, studies evaluating ICU-admitted patients at six months post-COVID observed significantly lower FEV1 and FVC values compared to healthy controls, with preserved or increased FEV1/FVC ratios indicative of restrictive lung dysfunction [4]. Huntley et al. also reported mild reductions in FVC and TLC three months after SARS and COVID-19 infections, suggesting restrictive impairment [36]. Conversely, an Italian study evaluating PFT outcomes approximately three months after COVID-19 found no significant differences in pulmonary function according to disease severity [40]. In our study, stratification of PFT parameters by CO-RADS categories revealed no significant differences, aligning with a retrospective study that found over half of COVID-19 patients exhibited restrictive or low diffusion patterns one month after symptom onset, without a significant correlation between CT severity scores and PFT result [41]. Taken together, these findings indicate that severe/critical COVID-19 and ICU admission are associated with post-acute restrictive lung involvement and impaired pulmonary function, whereas CO-RADS categories at diagnosis may predict early clinical and laboratory outcomes but not early post-COVID PFT results. In the present study, no significant association was found between disease severity and 6MWT outcomes. Similarly, Rinaldo et al. reported that disease severity did not influence exercise capacity in COVID-19 survivors assessed three months after discharge [40]. In contrast, Strumiliene et al. found a negative correlation between disease severity and 6MWT performance in patients evaluated two months after hospitalization for COVID-19 pneumonia [35]. These discrepancies may be explained by differences in sample size, follow-up duration, rehabilitation practices, and baseline physical status of the participants. Although no relationship was found between disease severity and CT findings or 6MWT distance in our cohort, overall exercise capacity remained reduced compared to healthy individuals [42]. Consistent with previous studies, a substantial proportion of post-COVID-19 patients do not achieve full recovery, with diminished exercise tolerance reported in the majority [43, 44]. The reduced exercise capacity may be attributed to muscle wasting and myopathy, which can result from systemic corticosteroid therapy and prolonged hospitalization leading to muscle loss and physical deconditioning [45]. In addition, elevated inflammatory markers observed in our study, including increased neutrophil–lymphocyte ratio and ferritin levels, may reflect a persistent systemic inflammatory response contributing to muscle catabolism and impaired functional capacity, as supported by studies demonstrating the association between inflammation, NLR, and sarcopenia [46]. Discrepancies between radiological severity and exercise capacity may be observed during early follow-up, as overall exercise limitation can occur independently of radiological findings in post-COVID-19 patients. These results highlight the importance of evaluating functional capacity in the post-acute phase and suggest that pulmonary rehabilitation strategies aimed at improving exercise performance should be integrated into the early post-COVID period management of COVID-19 survivors. This study evaluated the associations between clinical severity and early laboratory and chest CT findings in hospitalized patients with COVID-19 pneumonia, as well as their impact on pulmonary function and exercise capacity in the post-COVID period. However, several limitations should be acknowledged. Baseline data on CT findings and exercise capacity prior to COVID-19 infection were not available; nevertheless, individuals with known pre-existing cardiopulmonary conditions were excluded to minimize potential confounding. Additionally, follow-up laboratory tests were not conducted in the post-COVID period to avoid unnecessary invasive procedures, and repeat chest CT imaging was not performed to prevent radiation exposure. Moreover, the clinic where the study was conducted lacked advanced equipment necessary for certain assessments, such as total lung capacity measurement via body plethysmography or gas dilution techniques. Consequently, we relied on non-invasive methods, including PFT and 6MWT, to evaluate post-COVID-19 pulmonary and functional status. Detailed information regarding non-invasive ventilation, invasive mechanical ventilation, and the duration of ventilatory support was not consistently available in the retrospective hospital records, and therefore could not be analyzed. Pulmonary function was assessed at two months post-discharge, which represents an early follow-up; longer-term evaluations at three months or later may provide a more accurate assessment of restrictive impairment and should be considered in future studies. Several factors, including age, sex, BMI, comorbidities, and ICU admission, may influence PFT and 6MWT outcomes. However, due to the limited sample size and retrospective study design, multivariable regression analysis could not be performed; therefore, the absence of adjustment for potential confounders is acknowledged as a limitation. Furthermore, the single-center design and relatively small sample size, especially in certain CO-RADS subgroups, limit the statistical power and generalizability of the findings. Therefore, caution is advised when extrapolating these results to larger populations, and future multi-center studies with larger cohorts are warranted to validate and expand upon our findings. Conclusion In conclusion, among patients hospitalized with COVID-19 pneumonia, those who were older, male, had a high BMI, multiple comorbidities, elevated inflammatory markers at admission—including CRP, ferritin, D-dimer, neutrophil %, and N/L ratio—low lymphocyte %, and CO-RADS category 4–5 were more likely to experience severe or critical disease. Notably, patients requiring ICU admission demonstrated more pronounced restrictive pulmonary impairment, reduced FEV1 and FVC values and shorter 6MWT distance at two months post-discharge. Significant associations were observed between inflammatory laboratory parameters during hospitalization and early post-COVID period pulmonary function outcomes. Although no significant differences in 6MWT distances were observed across CO-RADS categories or clinical severity groups, exercise capacity remained reduced compared to healthy individuals. These findings emphasize the critical role of ICU admission in predicting early post-COVID pulmonary and functional impairment. Drawing on lessons from previous viral pandemics, this study offers valuable insights that may aid clinicians in managing and prognosticating outcomes in future viral respiratory outbreaks; however, further research with longer-term follow-up of 3 to 5 years is needed to better understand the prolonged effects.